TABLE 3.
Top occurring SNPs among sequenced samples in the TB Portals program
| SNP | No. of sequenced samples with SNP | % of sequenced samples with SNP among total sequenced samples | Gene affected | Drug(s) against which SNP confers resistancea |
|---|---|---|---|---|
| katG-S315T | 477 | 75.8 | katG | Isoniazid |
| rpoB-S450L | 390 | 62.0 | rpoB | Rifampin |
| gyrA-S95T | 360 | 57.2 | gyrA | Ofloxacin, moxifloxacin |
| rpsL-K43R | 251 | 39.9 | rpsL | Streptomycin |
| rrs-A1400G | 129 | 20.5 | rrs | Amikacin, kanamycin, capreomycin |
| rpsL-K88R | 121 | 19.2 | rpsL | Streptomycin |
| embB-M306V | 116 | 18.4 | embB | Ethambutol |
| embB-M306I | 95 | 15.1 | embB | Ethambutol |
| gyrA-D94G | 89 | 14.1 | gyrA | Ofloxacin |
| gyrA-A90V | 69 | 11.0 | gyrA | Ofloxacin |
| inhA-C15T | 63 | 10.0 | inhA | Isoniazid |
a
SNPs described by the ReSeqTB database (https://platform.reseqtb.org/) as having either “large and often conclusive evidence” or “moderate evidence for drug resistance.”